The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
600
Blood is taken to analyse degradation products of the metabolism of amyloid
Ghent university hospital
Ghent, Belgium
RECRUITINGDegradation products of the Amyloid metabolism in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. Different laboratory analysis will be performed to evaluate the degradation products of the metabolism of amyloid in blood. Different parts of the degradation products will be analysed namely: Plasma total-tau
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.
Degradation products of the Amyloid metabolism in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. Different laboratory analysis will be performed to evaluate the degradation products of the metabolism of amyloid in blood. Different parts of the degradation products will be analysed namely: Nurofilament light chain
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.
Degradation products of the Amyloid metabolism in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. Different laboratory analysis will be performed to evaluate the degradation products of the metabolism of amyloid in blood. Different parts of the degradation products will be analysed namely: Abeta1-40
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.
Degradation products of the Amyloid metabolism in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. Different laboratory analysis will be performed to evaluate the degradation products of the metabolism of amyloid in blood. Different parts of the degradation products will be analysed namely: Abeta1-42
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Degradation products of the Amyloid metabolism in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. Different laboratory analysis will be performed to evaluate the degradation products of the metabolism of amyloid in blood. Different parts of the degradation products will be analysed namely: YKL-40
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.
Degradation products of the Amyloid metabolism in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. Different laboratory analysis will be performed to evaluate the degradation products of the metabolism of amyloid in blood. Different parts of the degradation products will be analysed namely: Neurogranin
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.
APOE-genotyping in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. APOE-genotyping will be performed
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.
identify BACE1 in blood
The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. BACE1 will also be identified in the blood.
Time frame: 2 years after the first patient was included, the first batch of samples will be analysed.